Leading the research, Professor Julia Hippisley-Cox, said: “Ovarian cancer is notoriously difficult to spot and we hope that this new tool will help GPs identify patients most at risk of having ovarian cancer for early referral and investigations.”
Ovarian cancer is the seventh most common cancer in women worldwide and affects around 6,700 women in the UK every year, one of the highest rates in Europe. Most women are diagnosed when the disease is already at an advanced stage, meaning that in many cases their chances of surviving for five years after diagnosis can be as low as six per cent.
Less than one-third of women are diagnosed in the first stages of the disease but of those 90 per cent will survive to five years, showing that earlier diagnosis and treatment can have a dramatic impact on the patient’s chances of survival.
However, GPs are faced with the tough challenge of making a correct diagnosis as early as possible for a disease which has few established risk factors and a range of non-specific symptoms such as loss of appetite, weight loss and abdominal pain which could also point to a number of less serious and more common conditions.
For the study, the academics used anonymous data from 564 GPs surgeries using the QResearch® database system — a not-for-profit partnership between The University of Nottingham and leading GPs systems supplier EMIS.
They included information for female patients aged 30 to 84 who had not previously been diagnosed with ovarian cancer and did not have one of a number of ‘red flag’ symptoms in the previous 12 months.
They assessed risk factors including age, family history, previous diagnosis of other forms of cancer, loss of appetite, weight loss, abdominal distension, rectal bleeding, postmenopausal bleeding and anaemia to predict which patients were most at risk of having ovarian cancer and combined these in the risk prediction algorithm.
The tool was successful in predicting 63 per cent of all ovarian cancers over the following two years which were in the top 10 per cent of women found to be most at risk.
In addition to detecting cancer at an earlier stage, the tool could help GPs to direct their scarce resources such as ultrasonography, MRI scans and blood tests, to the patients more urgently in need of further investigation.
It is in line with current Government policy and the National Awareness and Early Diagnosis Initiative (NAEDI) — a public/third sector partnership between the Department of Health, National Cancer Action Team and Cancer Research UK.
The simple web-based calculator — http://www.qcancer.org/ovary — is designed for doctors but a simpler version could also be made available on the internet to raise awareness among the general public and to prompt women with risk factors or symptoms to seek advice from their doctor. It could also be integrated into GP clinical computer systems for use during the consultation or for identifying patients with combinations of symptoms needing further assessment.
Similar scores using QResearch® have already proven effective in previous research in identifying patients at most risk of developing lung cancer, gastro-oesophageal cancer, bowel cancer, pancreatic cancer, heart disease, type 2 diabetes, fractures, kidney disease and serious blood clots.
Professor Hippisley-Cox added: “We are very grateful for the continuing support of the EMIS GP practices that contribute their high quality data to QResearch. Without them, our research would not be possible.”
— Ends —
Notes to editors: This research was undertaken using the QResearch® anonymised primary care database at The University of Nottingham.
QResearch® is a non-profit making venture run by The University of Nottingham in collaboration with EMIS. More than 600 EMIS practices, representing around eight million patients, regularly contribute to the database. The system anonymises and uploads practices’ clinical data to the central database. Then, to protect patient confidentiality, the data are further anonymised and the figures are totalled to produce data that are suitable for research. (www.qresearch.org).
EMIS Group* is the UK’s leading supplier of healthcare software and related services to GP practices. www.emis-online.com
ClinRisk Ltd is a medical research and software company which provides open and closed source software to implement algorithms in clinical computer systems.
The University of Nottingham, described by The Sunday Times University Guide 2011 as ‘the embodiment of the modern international university’, has award-winning campuses in the United Kingdom, China and Malaysia. It is ranked in the UK’s Top 10 and the World's Top 75 universities by the Shanghai Jiao Tong (SJTU) and the QS World University Rankings. It was named ‘the world’s greenest university’ in the UI GreenMetric World University Ranking 2011, a league table of the most environmentally-friendly higher education institutions.
The University is committed to providing a truly international education for its 40,000 students, producing world-leading research and benefiting the communities around its campuses in the UK and Asia. Impact: The Nottingham Campaign, its biggest ever fund-raising campaign, will deliver the University’s vision to change lives, tackle global issues and shape the future. For more details, visit: www.nottingham.ac.uk/impactcampaign
More than 90 per cent of research at The University of Nottingham is of international quality, according to the most recent Research Assessment Exercise, with almost 60 per cent of all research defined as ‘world-leading’ or ‘internationally excellent’. Research Fortnight analysis of RAE 2008 ranked the University 7th in the UK by research power.
The University’s vision is to be recognised around the world for its signature contributions, especially in global food security, energy & sustainability, and health. The University won a Queen’s Award for Higher and Further Education in 2011, for its research on global food security.
More news from the University at: www.nottingham.ac.uk/news
* EMIS is a registered trademark of Egton Medical Information Systems Limited. Registered In England. No 2117205. Registered Office: Fulford Grange, Micklefield Lane, Rawdon, Leeds, LS19 6BA.